Baird analyst Jack Allen upgraded Allogene Therapeutics to Outperform from Neutral with an unchanged price target of $12.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on ALLO:
- Allogene Therapeutics initiated with a Buy at EF Hutton
- Allogene Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference
- Zai Lab appoinst Amado as President, Head of Global Oncology R&D
- Allogene Therapeutics appoints Zachary Roberts as EVP, research and development
- Allogene Appoints Zachary J. Roberts, M.D., Ph.D. as Executive Vice President of Research & Development